Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-20260415-221737",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": 1,\n      \"title\": \"TREM2 Agonism as Neuroprotective Strategy in Alzheimer's Disease\",\n      \"target\": \"TREM2\",\n      \"composite_score\": 0.59,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.75,\n        \"evidence_strength\": 0.65,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.85,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.70,\n        \"reproducibility\": 0.55\n      },\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 R47H variant significantly increases AD risk (HR ~3.5)\", \"pmid\": \"24448038\"},\n        {\"claim\": \"TREM2 deficiency reduces microglial proliferation around plaques in 5xFAD mice\", \"pmid\": \"29395067\"},\n        {\"claim\": \"TREM2 haploinsufficiency in humans causes Nasu-Hakola disease with presenile dementia\", \"pmid\": \"21700621\"},\n        {\"claim\": \"TREM2 extracellular domain is crystallographically well-characterized and antibody-accessible\", \"pmid\": \"25938356\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Phase 2 AL002 trial failed primary endpoints despite robust target engagement\", \"pmid\": \"NCT05113862\"},\n        {\"claim\": \"AL002 Phase 2 discontinued for lack of efficacy\", \"pmid\": \"NCT05131555\"},\n        {\"claim\": \"Higher TREM2 expression in human AD brains correlates with worse cognitive outcomes\", \"pmid\": \"31601826\"},\n        {\"claim\": \"DAM state may propagate pathology in later disease stages rather than provide protection\", \"pmid\": \"30760988\"},\n        {\"claim\": \"Species differences in TREM2 expression patterns between mice and humans limit translation\", \"pmid\": \"29395067\"}\n      ],\n      \"key_insight\": \"Genetic risk reduction ≠ pharmacological activation; AL002 failure may reflect wrong disease stage rather than wrong mechanism\"\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": 5,\n      \"title\": \"Restoration of Glial NAD+ Metabolism as Broad Neuroprotective Approach\",\n      \"target\": \"SIRT1/NAD+ biosynthetic pathway\",\n      \"composite_score\": 0.555,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.60,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.50,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.55\n      },\n      \"evidence_for\": [\n        {\"claim\": \"NAD+ levels decline with aging and in neurodegeneration models\", \"pmid\": \"20400966\"},\n        {\"claim\": \"NR supplementation extends lifespan and improves mitochondrial function in aged mice\", \"pmid\": \"24077513\"},\n        {\"claim\": \"SIRT1 activation deacetylates and activates PGC-1α for mitochondrial biogenesis\", \"pmid\": \"18171937\"},\n        {\"claim\": \"NAD+ precursors are bioavailable small molecules with established safety profiles\", \"pmid\": \"31198021\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Limited BBB penetration - NMN raises plasma NMN but brain NMN remains essentially unchanged in humans\", \"pmid\": \"31198021\"},\n        {\"claim\": \"Clinical trials of NAD+ precursors in PD and AD show limited CNS biomarker effects\", \"pmid\": \"32745137\"},\n        {\"claim\": \"NAD+ decline may represent protective adaptive downregulation - supplementation could interfere\", \"pmid\": \"29540362\"},\n        {\"claim\": \"SIRT1-independent effects may predominate - PARP activation, CD38 activity equally affected\", \"pmid\": \"29669920\"}\n      ],\n      \"key_insight\": \"Delivery problem is fundamental pharmacokinetic issue; requires direct brain delivery (focused ultrasound, gene therapy) rather than systemic supplementation\"\n    },\n    {\n      \"rank\": 3,\n      \"hypothesis_id\": 4,\n      \"title\": \"Inhibiting LRRK2 Kinase Activity to Reduce Synuclein Pathology\",\n      \"target\": \"LRRK2\",\n      \"composite_score\": 0.525,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.85,\n        \"evidence_strength\": 0.70,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.65,\n        \"druggability\": 0.80,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.45,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.60\n      },\n      \"evidence_for\": [\n        {\"claim\": \"LRRK2 G2019S mutation causes 2-3 fold increased kinase activity\", \"pmid\": \"16856876\"},\n        {\"claim\": \"LRRK2 knockdown reduces alpha-synuclein-induced neurodegeneration in vivo\", \"pmid\": \"25186242\"},\n        {\"claim\": \"LRRK2 inhibitors (PF-360, MLi-2) rescue lysosomal defects in mutant fibroblasts\", \"pmid\": \"28661562\"},\n        {\"claim\": \"G2019S is most common genetic cause of PD (5-6% of all PD cases)\", \"pmid\": \"16856876\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Phase 2 LRRK2 inhibitor trials halted - DNL151 discontinued\", \"pmid\": \"NCT04063488\"},\n        {\"claim\": \"LRRK2 null mice viable with minimal neurodegeneration phenotype\", \"pmid\": \"24821972\"},\n        {\"claim\": \"Human LRRK2 more potently inhibited by current compounds than rodent - translational uncertainty\", \"pmid\": \"29305848\"},\n        {\"claim\": \"Kinase-independent functions of LRRK2 may cause pathology that inhibitors cannot address\", \"pmid\": \"28781056\"},\n        {\"claim\": \"LRRK2 knockout mice develop kidney lamellar body accumulation and lung pathology\", \"pmid\": \"24821972\"}\n      ],\n      \"key_insight\": \"Clinical development challenges (CNS penetration, toxicity) proved intractable; requires fundamentally new compounds targeting kinase-independent functions or allosteric modulators\"\n    },\n    {\n      \"rank\": 4,\n      \"hypothesis_id\": 6,\n      \"title\": \"C9orf72 Repeat Expansion Targeting with Antisense Oligonucleotides\",\n      \"target\": \"C9orf72 expanded repeat transcripts\",\n      \"composite_score\": 0.53,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.75,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.50,\n        \"therapeutic_potential\": 0.40,\n        \"druggability\": 0.85,\n        \"safety_profile\": 0.35,\n        \"competitive_landscape\": 0.40,\n        \"data_availability\": 0.80,\n        \"reproducibility\": 0.70\n      },\n      \"evidence_for\": [\n        {\"claim\": \"C9orf72 expansions are most common genetic cause of ALS and FTD\", \"pmid\": \"21944779\"},\n        {\"claim\": \"ASO treatment reduces toxic RNA foci and DPR proteins in patient-derived neurons\", \"pmid\": \"25374355\"},\n        {\"claim\": \"Phase 1/2 clinical trials demonstrate ASO safety and target engagement\", \"pmid\": \"NCT03601223\"},\n        {\"claim\": \"ASOs are well-established modality with validated chemistry for RNA targeting\", \"pmid\": \"25374355\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Phase 3 GENERATION study FAILED - BIIB078 showed trend toward worse outcomes, trial discontinued July 2023\", \"pmid\": \"NCT04161894\"},\n        {\"claim\": \"C9orf72 haploinsufficiency paradox - reducing toxic RNA ALSO reduces C9orf72 protein, potentially exacerbating pathology\", \"pmid\": \"25425648\"},\n        {\"claim\": \"Patient-derived neurons show heterogeneous responses to ASO treatment\", \"pmid\": \"28969958\"},\n        {\"claim\": \"Treatment timing in established ALS likely too late - neurobiological changes precede symptoms by years\", \"pmid\": \"28969958\"}\n      ],\n      \"key_insight\": \"Phase 3 failure suggests either wrong mechanism assumption (DPRs may be more pathogenic than RNA) or therapeutic paradox from C9orf72 haploinsufficiency; fundamental mechanism reconsideration needed\"\n    },\n    {\n      \"rank\": 5,\n      \"hypothesis_id\": 2,\n      \"title\": \"TFEB Activation to Restore Autophagy-Lysosomal Function in Parkinson's Disease\",\n      \"target\": \"TFEB (MITF/TFE family)\",\n      \"composite_score\": 0.485,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.70,\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.75,\n        \"feasibility\": 0.35,\n        \"therapeutic_potential\": 0.60,\n        \"druggability\": 0.30,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.25,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.45\n      },\n      \"evidence_for\": [\n        {\"claim\": \"TFEB overexpression reduces alpha-synuclein aggregation in cellular models\", \"pmid\": \"23392613\"},\n        {\"claim\": \"mTORC1 inhibition via rapamycin enhances TFEB nuclear translocation and autophagy\", \"pmid\": \"21617036\"},\n        {\"claim\": \"Lysosomal storage defects (GBA mutations) increase alpha-synuclein aggregation\", \"pmid\": \"18668040\"},\n        {\"claim\": \"TFEB regulates lysosomal biogenesis and autophagy - core pathway in synucleinopathy\", \"pmid\": \"23392613\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Constitutive TFEB gain-of-function causes focal cytoplasmic sequestration and lysosomal storage disease\", \"pmid\": \"21471978\"},\n        {\"claim\": \"Autophagy-inducers increase α-synuclein in some contexts by overwhelming lysosomal capacity\", \"pmid\": \"25339209\"},\n        {\"claim\": \"No selective TFEB activator exists - all tool compounds work through mTOR inhibition with pleiotropic effects\", \"pmid\": \"21617036\"},\n        {\"claim\": \"Late intervention studies in established pathology models show markedly reduced efficacy\", \"pmid\": \"27569042\"}\n      ],\n      \"key_insight\": \"Biologically plausible but pharmacologically immature - no selective pharmacological tool exists; therapeutic window between beneficial autophagy and pathological overactivation is narrow and undefined\"\n    },\n    {\n      \"rank\": 6,\n      \"hypothesis_id\": 3,\n      \"title\": \"Nurr1 Agonism to Suppress Neuroinflammatory Cascade in Parkinsonian Disorders\",\n      \"target\": \"Nurr1 (NR4A2)\",\n      \"composite_score\": 0.48,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.65,\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.55,\n        \"druggability\": 0.50,\n        \"safety_profile\": 0.50,\n        \"competitive_landscape\": 0.30,\n        \"data_availability\": 0.40,\n        \"reproducibility\": 0.45\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Nurr1 knockdown causes progressive dopaminergic neuron loss in knock-in mice\", \"pmid\": \"12084553\"},\n        {\"claim\": \"Nurr1 forms transrepression complexes with NF-κB to inhibit inflammatory mediators\", \"pmid\": \"19808673\"},\n        {\"claim\": \"Nurr1 agonists reduce microglial activation and protect dopaminergic neurons\", \"pmid\": \"25212984\"},\n        {\"claim\": \"Nurr1 is expressed in both dopaminergic neurons and surrounding glial cells\", \"pmid\": \"19808673\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"No selective CNS-penetrant Nurr1 agonist has reached IND stage - every compound has off-target effects\", \"pmid\": \"25399196\"},\n        {\"claim\": \"Nurr1 agonists have stalled in development - undisclosed pharmacological barriers\", \"pmid\": \"25399196\"},\n        {\"claim\": \"Functional redundancy with NR4A1 (Nurr77) and NR4A3 (Nor-1) may reduce single-target efficacy\", \"pmid\": \"16782802\"},\n        {\"claim\": \"Nurr1 knockout is perinatal lethal in mice - developmental essentiality raises safety flags\", \"pmid\": \"12084553\"}\n      ],\n      \"key_insight\": \"This is a hypothesis-stage target, not a drug development-stage target; requires 8-12 years of dedicated medicinal chemistry investment to generate selective CNS-penetrant agonists\"\n    },\n    {\n      \"rank\": 7,\n      \"hypothesis_id\": 7,\n      \"title\": \"Modulating Cholesterol Metabolism to Reduce Aβ Production\",\n      \"target\": \"SREBP2\",\n      \"composite_score\": 0.38,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.50,\n        \"evidence_strength\": 0.35,\n        \"novelty\": 0.30,\n        \"feasibility\": 0.25,\n        \"therapeutic_potential\": 0.30,\n        \"druggability\": 0.55,\n        \"safety_profile\": 0.40,\n        \"competitive_landscape\": 0.20,\n        \"data_availability\": 0.35,\n        \"reproducibility\": 0.40\n      },\n      \"evidence_for\": [\n        {\"claim\": \"Cholesterol-rich lipid rafts facilitate amyloidogenic APP processing\", \"pmid\": \"10436096\"},\n        {\"claim\": \"HMG-CoA reductase inhibitors (statins) reduce Aβ production in vitro\", \"pmid\": \"12556232\"},\n        {\"claim\": \"SREBP2 activation increases β-secretase (BACE1) expression\", \"pmid\": \"23748564\"},\n        {\"claim\": \"SREBP2 is structurally characterized and indirect targeting is feasible\", \"pmid\": \"23748564\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Multiple large-scale statin RCTs for AD prevention/treatment consistently FAILED - CLASP, LEADe, GS arbitrary trials\", \"pmid\": \"21849526\"},\n        {\"claim\": \"Brain cholesterol is largely independent of peripheral cholesterol - BBB isolates brain pools\", \"pmid\": \"21592732\"},\n        {\"claim\": \"Neuronal cholesterol synthesis is essential for synapse function - broad inhibition causes axonal degeneration\", \"pmid\": \"24958850\"},\n        {\"claim\": \"No pharmaceutical company is actively pursuing SREBP2 inhibitors for neurodegeneration\", \"pmid\": \"21849526\"}\n      ],\n      \"key_insight\": \"Most clinically dead hypothesis on the list; statin trial database is extensive and consistently negative - thousands of patients across multiple RCTs uniformly negative\"\n    }\n  ],\n  \"knowledge_edges\": [\n    {\n      \"source\": \"TREM2\",\n      \"target\": \"TYROBP\",\n      \"edge_type\": \"protein_protein_interaction\",\n      \"pathway\": \"Microglial signaling cascade\",\n      \"directionality\": \"bidirectional\"\n    },\n    {\n      \"source\": \"TREM2\",\n      \"target\": \"CSF1R\",\n      \"edge_type\": \"pathway_crosstalk\",\n      \"pathway\": \"Microglial proliferation\",\n      \"directionality\": \"parallel\"\n    },\n    {\n      \"source\": \"LRRK2\",\n      \"target\": \"GBA\",\n      \"edge_type\": \"shared_pathway\",\n      \"pathway\": \"Autophagy-lysosomal dysfunction\",\n      \"directionality\": \"convergent\"\n    },\n    {\n      \"source\": \"LRRK2\",\n      \"target\": \"RAB proteins (RAB7, RAB8A, RAB10)\",\n      \"edge_type\": \"phosphorylation_target\",\n      \"pathway\": \"Endosomal-lysosomal trafficking\",\n      \"directionality\": \"downstream\"\n    },\n    {\n      \"source\": \"TFEB\",\n      \"target\": \"mTORC1\",\n      \"edge_type\": \"regulatory\",\n      \"pathway\": \"Autophagy-lysosomal biogenesis\",\n      \"directionality\": \"inhibitory\"\n    },\n    {\n      \"source\": \"TFEB\",\n      \"target\": \"LAMP1/2, CTSD\",\n      \"edge_type\": \"transcriptional_regulation\",\n      \"pathway\": \"Lysosomal enzyme expression\",\n      \"directionality\": \"upstream\"\n    },\n    {\n      \"source\": \"NAD+\",\n      \"target\": \"SIRT1\",\n      \"edge_type\": \"enzyme_substrate\",\n      \"pathway\": \"Mitochondrial biogenesis\",\n      \"directionality\": \"upstream\"\n    },\n    {\n      \"source\": \"SIRT1\",\n      \"target\": \"PGC-1α\",\n      \"edge_type\": \"deacetylation_activation\",\n      \"pathway\": \"Mitochondrial function\",\n      \"directionality\": \"activating\"\n    },\n    {\n      \"source\": \"SREBP2\",\n      \"target\": \"BACE1\",\n      \"edge_type\": \"transcriptional_regulation\",\n      \"pathway\": \"Amyloidogenic APP processing\",\n      \"directionality\": \"upstream\"\n    },\n    {\n      \"source\": \"SREBP2\",\n      \"target\": \"HMGCR\",\n      \"edge_type\": \"transcriptional_regulation\",\n      \"pathway\": \"Cholesterol biosynthesis\",\n      \"directionality\": \"upstream\"\n    },\n    {\n      \"source\": \"C9orf72\",\n      \"target\": \"RAN translation\",\n      \"edge_type\": \"pathological_process\",\n      \"pathway\": \"Dipeptide repeat protein synthesis\",\n      \"directionality\": \"source\"\n    },\n    {\n      \"source\": \"C9orf72\",\n      \"target\": \" autophagy\",\n      \"edge_type\": \"function\",\n      \"pathway\": \"Lysosomal trafficking\",\n      \"directionality\": \"regulatory\"\n    },\n    {\n      \"source\": \"Nurr1\",\n      \"target\": \"NF-κB\",\n      \"edge_type\": \"transrepression\",\n      \"pathway\": \"Inflammatory response\",\n      \"directionality\": \"inhibitory\"\n    },\n    {\n      \"source\": \"Nurr1\",\n      \"target\": \"TH, DAT\",\n      \"edge_type\": \"transcriptional_regulation\",\n      \"pathway\": \"Dopaminergic neuron maintenance\",\n      \"directionality\": \"upstream\"\n    },\n    {\n      \"source\": \"α-synuclein\",\n      \"target\": \"GBA\",\n      \"edge_type\": \"pathological_interaction\",\n      \"pathway\": \"Synucleinopathy\",\n      \"directionality\": \"bidirectional\"\n    },\n    {\n      \"source\": \"α-synuclein\",\n      \"target\": \"LRRK2\",\n      \"edge_type\": \"pathological_interaction\",\n      \"pathway\": \"PD pathogenesis\",\n      \"directionality\": \"bidirectional\"\n    }\n  ],\n  \"synthesis_summary\": {\n    \"overview\": \"Analysis of seven neurodegeneration therapeutic hypotheses reveals a consistent pattern: strong genetic validation fails to translate to clinical success, primarily due to species differences, timing/staging issues, and single-target approaches for multifactorial diseases. The most advanced programs (TREM2, LRRK2, C9orf72 ASOs) have all experienced clinical setbacks.\",\n    \n    \"top_3_recommendations\": [\n      {\n        \"rank\": 1,\n        \"hypothesis\": \"TREM2 Agonism\",\n        \"recommendation\": \"REDIRECT - Test in genetically-selected, EARLY-STAGE/PRESYMPTOMATIC patients using humanized mouse models\",\n        \"rationale\": \"AL002 failure may reflect wrong disease stage rather than wrong mechanism; R47H variant biology suggests microglial modulation remains viable if timing is corrected\",\n        \"estimated_cost\": \"$80-120M\",\n        \"timeline\": \"3-5 years with existing antibodies\"\n      },\n      {\n        \"rank\": 2,\n        \"hypothesis\": \"NAD+ Restoration with Direct CNS Delivery\",\n        \"recommendation\": \"PIVOT - Redirect from systemic supplementation to focused ultrasound BBB opening + NMN, or AAV-mediated gene therapy\",\n        \"rationale\": \"BBB delivery problem is fundamental pharmacokinetic limitation; direct brain delivery methods may unlock therapeutic potential\",\n        \"estimated_cost\": \"$50-80M\",\n        \"timeline\": \"4-6 years\"\n      },\n      {\n        \"rank\": 3,\n        \"hypothesis\": \"TFEB Activation with Selective Compounds\",\n        \"recommendation\": \"INVEST - Support development of selective TFEB activators (not mTOR inhibitors) with defined therapeutic windows\",\n        \"rationale\": \"Biologically plausible mechanism not yet clinically tested in PD; requires medicinal chemistry investment to generate selective tool compounds\",\n        \"estimated_cost\": \"$200-300M\",\n        \"timeline\": \"7-10 years\"\n      }\n    ],\n    \n    \"critical_cross-cutting_themes\": [\n      {\n        \"theme\": \"Prevention vs. Treatment Gap\",\n        \"description\": \"All hypotheses tested in young animals with acute pathology; human neurodegeneration develops over 20-30 years. The biology of established, decade-old aggregates may be fundamentally different.\",\n        \"implication\": \"Clinical trials should enroll presymptomatic or very early-stage patients; current trial designs in established disease may be systematically underpowered.\"\n      },\n      {\n        \"theme\": \"Species Neuroimmune Differences\",\n        \"description\": \"Human microglia are transcriptionally distinct from mouse microglia; disease-associated microglia (DAM) states in humans may propagate rather than suppress pathology.\",\n        \"implication\": \"Humanized mouse models, patient-derived neurons, and non-human primate studies are essential but underutilized.\"\n      },\n      {\n        \"theme\": \"Genetic Validation ≠ Pharmacological Tractability\",\n        \"description\": \"TREM2 (R47H), LRRK2 (G2019S), and C9orf72 (expansion) represent strongest genetic evidence for any targets, yet all have failed clinically.\",\n        \"implication\": \"Genetic risk reduction through partial loss-of-function may not be equivalent to pharmacological activation or inhibition.\"\n      },\n      {\n        \"theme\": \"Single-Target Limitations\",\n        \"description\": \"AD, PD, ALS, FTD each involve multiple convergent pathogenic mechanisms; single-node intervention is inherently insufficient.\",\n        \"implication\": \"Combination therapies targeting multiple pathways simultaneously may be required for meaningful clinical benefit.\"\n      },\n      {\n        \"theme\": \"Biomarker Gaps\",\n        \"description\": \"Without CNS biomarkers of target engagement, Phase 2 trials operate blind; AL002 demonstrated robust biomarker engagement with zero clinical benefit.\",\n        \"implication\": \"Biomarker development should precede or parallel clinical development programs.\"\n      }\n    ],\n    \n    \"hypotheses_to_deprioritize\": [\n      {\n        \"hypothesis\": \"C9orf72 ASOs\",\n        \"reason\": \"Phase 3 failure with trend toward worse outcomes; mechanism in question; requires fundamental reconsideration before further investment\",\n        \"confidence\": 0.30\n      },\n      {\n        \"hypothesis\": \"Nurr1 Agonism\",\n        \"reason\": \"No selective CNS-penetrant agonist exists; 8-12 year timeline to first-in-human study; not currently investable\",\n        \"confidence\": 0.45\n      },\n      {\n        \"hypothesis\": \"SREBP2/Cholesterol Modulation\",\n        \"reason\": \"Most clinically dead hypothesis; extensive statin trial database (thousands of patients) consistently negative; do not invest\",\n        \"confidence\": 0.35\n      }\n    ]\n  }\n}\n```",
  "tokens_used": "5268",
  "persona_id": "persona-synthesizer"
}